Table 3

Incremental and endurance walking capacity, fat-free mass, quadriceps strength and quality of life at baseline and 3 months

UC (n=26)PEPR (n=23)PEPR vs UC
Baseline3 monthsBaseline3 monthsDifference (95% CI), p value*
Weight (kg)79.8 (20.3)80.2 (19.9)77.7 (23.3)77.8 (22.7)−0.2 (−2.5 to 2.1), p=0.86
FFM (kg)49.1 (10.5)49.9 (11.2)48.9 (8.3)49.5 (8.3)−0.2 (1.8 to 1.4), p=0.78
QMVC (kg)25.6 (13.1)24.4 (13.2)22.3 (7.2)26.2 (8.9)5.1 (2.5 to 7.6), p<0.01
ISW (m)165 (96)183 (98)147 (98)216 (126)51 (22 to 79), p<0.01
 Borg score (0–10)3.9 (1.8)3.7 (1.7)4.2 (2.0)4.4 (1.5)0.4 (−0.7 to 1.6), p=0.48
 Leg fatigue (0–10)3.5 (2.6)3.5 (2.3)2.2 (2.2)2.7 (2.5)0.5 (−0.7 to 1.7), p=0.38
ESW (m)224 (175)224 (133)214 (402)402 (400)189 (28 to 350), p=0.02
 Borg score (0–10)3.7 (1.3)4.0 (1.9)4.2 (1.8)4.3 (1.6)−0.2 (−1.7 to 1.3), p=0.81
 Leg fatigue (0–10)3.8 (2.1)3.2 (1.9)2.6 (2.2)2.9 (2.4)0.9 (−0.6 to 2.3), p=0.23
SGRQ Symptoms75.3 (16.5)77.6 (15.5)75.6 (16.0)74.9 (15.4)−2.8 (−10.0 to 4.5), p=0.44
SGRQ Activities72.0 (18.3)76.2 (15.4)79.5 (18.1)69.6 (19.4)−10.0 (−19.0 to −1.0), p=0.03
SGRQ Impacts43.5 (20.7)48.0 (19.3)49.4 (18.5)43.2 (15.8)−7.5 (−16.6 to 1.6), p=0.10
SGRQ Total57.4 (16.8)61.4 (14.7)64.1 (16.9)56.5 (13.7)−8.2 (−15.1 to −1.3), p=0.02
CRDQ Dyspnoea2.3 (1.1)2.5 (0.9)2.3 (0.8)3.3 (1.5)0.8 (0.1 to 1.5), p=0.03
CRDQ Fatigue2.8 (1.3)3.1 (1.3)3.1 (1.1)3.6 (1.4)0.3 (−0.3 to 1.0), p=0.34
CRDQ Emotion3.6 (1.2)3.8 (1.5)4.1 (1.1)4.8 (1.4)0.8 (0 to 1.7), p=0.05
CRDQ Mastery3.3 (1.6)4.0 (1.6)3.7 (1.4)4.5 (1.2)0.4 (−0.4 to 1.2), p=0.32
EQ5D VAS54 (17)61 (15)58 (18)68 (17)5 (−4 to 14), p=0.29
  • * ANCOVA.

  • Within group differences and differences between UC and PEPR groups shown.

  • CRDQ, Chronic Respiratory Disease Questionnaire; ESW, endurance walking capacity; FFMI, fat-free mass index; ISW, incremental walking capacity; PEPR, post-exacerbation pulmonary rehabilitation; QMVC, quadriceps maximum voluntary contraction; SGRQ, St George Respiratory Questionnaire; UC, usual care; VAS, visual analogue scale.